Not applicableLooking for participantsNCT01689584What this trial is testingCOsegregation of VARiants in Panel of GenesWho this might be right forGene Mutation-Related CancerGenetic Predisposition Institut Curie 3,500
Testing effectiveness (Phase 2)UnknownNCT05340413What this trial is testingPredicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.Who this might be right forHER2-negative Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer SOLTI Breast Cancer Research Group 63
Large-scale testing (Phase 3)Study completedNCT02184195What this trial is testingOlaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyWho this might be right forGermline BRCA1/2 Mutations andMetastatic Adenocarcinoma of the Pancreas AstraZeneca 154
Not applicableStudy completedNCT04108117What this trial is testingSurgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate ReconstructionWho this might be right forPostoperative ComplicationsRecurrenceBreast Neoplasms+5 more Severance Hospital 659
Testing effectiveness (Phase 2)WithdrawnNCT01661868What this trial is testingOlaparib for Patients With Recurrent BRCA Deficient Ovarian CancerWho this might be right forOvarian CancerPeritoneal CancerFallopian Tube Cancer Dana-Farber Cancer Institute
Early research (Phase 1)Looking for participantsNCT06488378What this trial is testingPhase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerWho this might be right forBreast CancerPALB2-Mutated Breast CarcinomaHER2-negative Breast Cancer+2 more Dana-Farber Cancer Institute 20
Early research (Phase 1)Looking for participantsNCT06177171What this trial is testingOlaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated TumorsWho this might be right forBRCA1 MutationBRCA2 MutationBRCA Mutation+3 more Pamela Munster 18
Not applicableStudy completedNCT01097278What this trial is testingS0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast CancerWho this might be right forbrca1 Mutation Carrierbrca2 Mutation CarrierBreast Cancer SWOG Cancer Research Network 208
Not applicableActive Not RecruitingNCT02760849What this trial is testingSurgery in Preventing Ovarian Cancer in Patients With Genetic MutationsWho this might be right forDeleterious BARD1 Gene MutationDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene Mutation+11 more M.D. Anderson Cancer Center 374
Not applicableUnknownNCT04983628What this trial is testingMolecular Profiling in Prostate CancerWho this might be right forProstate Cancer MetastaticProstate Cancer RecurrentGermline BRCA1 Gene Mutation+2 more Hellenic Cooperative Oncology Group 250
Large-scale testing (Phase 3)Ended earlyNCT00617656What this trial is testingStudy to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung CarcinomaWho this might be right forNon Small Cell Lung CancerBRCA1 Mutation Spanish Lung Cancer Group 382
Not applicableStudy completedNCT00098800What this trial is testingFenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the OvariesWho this might be right forbrca1 Mutation Carrierbrca2 Mutation CarrierOvarian Cancer University of Arizona 40
Testing effectiveness (Phase 2)Looking for participantsNCT05485766What this trial is testingNovel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast CancerWho this might be right forTriple Negative Breast NeoplasmsTriple Negative Breast CancerBreast Neoplasms+5 more Okayama University 23
Not applicableStudy completedNCT05750719What this trial is testingBRCA and NACT in TNBC PatientsWho this might be right forTriple-Negative Breast Cancer Fondazione Policlinico Universitario Agostino Gemelli IRCCS 136
Testing effectiveness (Phase 2)Ended earlyNCT02326844What this trial is testingBMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor TreatmentWho this might be right forOvarian Cancer National Cancer Institute (NCI) 3
Early research (Phase 1)Study completedNCT03509636What this trial is testingFluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian CancerWho this might be right forOvarian Cancer Jiangsu HengRui Medicine Co., Ltd. 113
Not applicableStudy completedNCT03684733What this trial is testingMagnetic Resonance Breast Tissue Characterisation to Improve Risk Stratification for Breast CancerWho this might be right forBRCA1 MutationBRCA2 MutationMammography+1 more Royal Marsden NHS Foundation Trust 28
Testing effectiveness (Phase 2)WithdrawnNCT03032614What this trial is testingCombination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer PatientsWho this might be right forBreast Cancer Stage IVOvarian CancerBRCA1 Mutation+1 more The University of Texas Health Science Center at San Antonio
Early research (Phase 1)Active Not RecruitingNCT05358639What this trial is testingCombination of Olaparib and Navitoclax in Women with HGSC and TNBCWho this might be right forHigh Grade Serous CarcinomaTriple Negative Breast CancerOvarian Cancer Sunnybrook Health Sciences Centre 36
Not applicableUnknownNCT04368442What this trial is testingCohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic MutationWho this might be right forBreast Cancer Metastatic Samsung Medical Center 583